Evolving Management Strategies for Nonalcoholic Fatty Liver Disease-Targeting Primary Care Physicians.
作者信息
Yadav Yogesh, Syn Wing-Kin, Basu Rita
机构信息
Division of Endocrinology, Diabetes and Metabolism, University of Virginia, Charlottesville, Virginia.
Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina.
出版信息
Diabetes Technol Ther. 2019 Nov;21(11):611-618. doi: 10.1089/dia.2019.0158. Epub 2019 Jul 29.
Abstract
摘要
相似文献
1
Evolving Management Strategies for Nonalcoholic Fatty Liver Disease-Targeting Primary Care Physicians.非酒精性脂肪性肝病不断发展的管理策略——以基层医疗医生为目标群体
Diabetes Technol Ther. 2019 Nov;21(11):611-618. doi: 10.1089/dia.2019.0158. Epub 2019 Jul 29.
2
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.在退伍军人健康管理局中识别非酒精性脂肪性肝病的肝纤维化程度。
Dig Dis Sci. 2018 Sep;63(9):2259-2266. doi: 10.1007/s10620-018-5123-3. Epub 2018 May 19.
3
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.无创性纤维化模型诊断准确性：检测纤维化分期变化。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1877-1885.e5. doi: 10.1016/j.cgh.2018.12.031. Epub 2019 Jan 4.
4
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患儿肝纤维化评分的评估
Dig Dis Sci. 2015 May;60(5):1440-7. doi: 10.1007/s10620-014-3494-7. Epub 2014 Dec 25.
5
Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.脂肪变性严重程度影响非酒精性脂肪性肝病无创性纤维化检测的诊断性能。
Liver Int. 2018 Feb;38(2):331-341. doi: 10.1111/liv.13549. Epub 2017 Sep 5.
6
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.肥胖和丙氨酸氨基转移酶水平对非酒精性脂肪性肝病患者无创性工具诊断晚期肝纤维化的准确性的影响。
Am J Gastroenterol. 2019 Jun;114(6):916-928. doi: 10.14309/ajg.0000000000000153.
7
A practical clinical approach to liver fibrosis.肝纤维化的实用临床方法。
Singapore Med J. 2018 Dec;59(12):628-633. doi: 10.11622/smedj.2018145.
8
Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.血清标志物模型的开发以提高非酒精性脂肪性肝病中晚期纤维化的诊断准确性：新型LINKI算法与现有算法的比较
PLoS One. 2016 Dec 9;11(12):e0167776. doi: 10.1371/journal.pone.0167776. eCollection 2016.
9
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.肝脏硬度测量值与非酒精性脂肪性肝病纤维化评分联合可提高非酒精性脂肪性肝病患者严重肝纤维化的无创性诊断准确性。
Liver Int. 2015 May;35(5):1566-73. doi: 10.1111/liv.12584. Epub 2014 May 20.
10
Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.非酒精性脂肪性肝病中的肝纤维化——具有预后意义的诊断挑战
World J Gastroenterol. 2015 Oct 21;21(39):11077-87. doi: 10.3748/wjg.v21.i39.11077.
本文引用的文献
1
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: .4. 全面的医学评估和共病评估： 。
Diabetes Care. 2019 Jan;42(Suppl 1):S34-S45. doi: 10.2337/dc19-S004.
2
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.非酒精性脂肪性肝病：病因、诊断、心血管代谢后果和治疗策略。
Lancet Diabetes Endocrinol. 2019 Apr;7(4):313-324. doi: 10.1016/S2213-8587(18)30154-2. Epub 2018 Aug 30.
3
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.振动控制瞬时弹性成像评估非酒精性脂肪性肝病患者的纤维化和脂肪变性。
Clin Gastroenterol Hepatol. 2019 Jan;17(1):156-163.e2. doi: 10.1016/j.cgh.2018.04.043. Epub 2018 Apr 26.
4
Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent.在南亚裔人群中，脂肪性肝病中肝纤维化的非侵入性标志物不可靠。
Frontline Gastroenterol. 2018 Apr;9(2):115-121. doi: 10.1136/flgastro-2017-100865. Epub 2017 Nov 16.
5
Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.糖尿病影响非酒精性脂肪性肝病患者非侵入性纤维化模型对肝硬化和预后的预测。
Liver Int. 2018 Oct;38(10):1793-1802. doi: 10.1111/liv.13739. Epub 2018 Mar 31.
6
An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans.碳水化合物限制饮食对人类肝脂肪变性的快速代谢益处的综合理解。
Cell Metab. 2018 Mar 6;27(3):559-571.e5. doi: 10.1016/j.cmet.2018.01.005. Epub 2018 Feb 15.
7
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的临床流行病学和疾病负担。
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263.
8
Current and future pharmacological therapies for NAFLD/NASH.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的当前和未来药理学治疗方法。
J Gastroenterol. 2018 Mar;53(3):362-376. doi: 10.1007/s00535-017-1415-1. Epub 2017 Dec 16.
9
Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.吡格列酮治疗伴有或不伴有 2 型糖尿病的非酒精性脂肪性肝炎患者的反应。
Clin Gastroenterol Hepatol. 2018 Apr;16(4):558-566.e2. doi: 10.1016/j.cgh.2017.12.001. Epub 2017 Dec 7.
10
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
Zotero 插件